Investor Relations

We at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing and to silence tinnitus.

Auris Medical is the leading pioneer in the emerging field of cochlear (inner ear) therapies. We have two projects in advanced clinical development:

AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss.

We have additional projects under development and are further strengthening our pipeline through collaborations with leading academic institutions in this field.

 

View more

 

Auris Medical Third Quarter 2017 Financial Results
Tuesday, November 28, 2017 8:00 a.m. ET
Description

Dial in details, Participants:
Confirmation Code: ............. 4997511
Local - London, United Kingdom: +44(0)20 3427 0503
National free phone - United Kingdom: … 0800 279 4841
Local - Frankfurt, Germany: +49(0)69 2222 10620
National free phone – Germany:…0800 589 2673
Local - New York, United States of America: …+1646 254 3365
National free phone - United States of America:..1877 280 1254

Click here for webcast


Various statements that Auris Medical Holding makes on this website about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The terms 'may,' 'will,' 'could,' 'anticipate,' 'plan,' 'continue,' 'project,' 'intend,' 'estimate,' 'believe,' 'expect,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.

In addition, any forward-looking statements represent the company's views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing the company's views as of any date subsequent the date such statements are made.